Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ValveXchange Inc.

This article was originally published in Start Up

Executive Summary

In heart valve surgery, there have been no home runs yet among the numerous efforts to improve the durability of tissue valves. ValveXchange Inc. has a different solution: improving the way that worn valves are replaced. The start-up is developing a tissue valve with exchangeable leaflets that can be exchanged either percutaneously or via minimally invasive techniques. By focusing on the replacement procedure, ValveXchange aims to make bioprosthetic valves more attractive to the increasingly younger patient population for whom its faster and safer exchange technology will provide a lifetime solution.

You may also be interested in...



Start-Up Previews (01/08)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "NOTES Companies Sing an Upbeat Tune," and "Solid Support for Flu Vaccine Development." Plus these Start-Ups Across Health Care: Carigent Therapeutics, Cizzle Biotechnology, Genesis Medical Interventional, and ValveXchange.

Start-Up Previews (01/08)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "NOTES Companies Sing an Upbeat Tune," and "Solid Support for Flu Vaccine Development." Plus these Start-Ups Across Health Care: Carigent Therapeutics, Cizzle Biotechnology, Genesis Medical Interventional, and ValveXchange.

Evalve, Mitralign Deals: Heart Valves Draw New Device Investors

Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel